Hemophilia
Advertisement
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.
Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A.
Patients with hemophilia A or B had low rates of VTE after total joint replacement despite infrequent thromboprophylaxis use.
Desmopressin was safe and effective for women with inherited bleeding disorders during both pregnancy and delivery.
Health Canada approved fidanacogene elaparvovec, an adenoviral vector-based gene therapy for patients with hemophilia B.
The FDA and EMA are expected to make decisions on once-weekly subcutaneous marstacimab for patients with hemophilia A or B.
Large deletions in the FVIII gene (F8) were shown to be predictors of ITI therapy failure.
Emicizumab plus ITI did not induce new safety signals in patients with hemophilia A.
A single infusion of AAV-HLP-hFVIII-V3 induced stable FVIII expression over five years.
Women with inherited bleeding disorders may need prophylaxis.
First patient treated with hemophilia A gene therapy demonstrates "promising" outcomes.
A study investigated clinical outcomes before and after pharmacokinetic (PK)-guided dosing for hemophilia.
Genicular artery embolization showed promising results in reducing synovial hyperemia in patients with hemophilia.
Poor bleeding rates seen despite flawed data across studies on congenital hemophilia A without inhibitors on FVIII treatment.
Simoctocog alfa was effective as prophylaxis or treatment for bleeding in treatment-naïve patients with severe hemophilia A.
Fitusiran significantly reduced the annualized bleeding rate in patients with severe hemophilia, even those with inhibitors.
In this episode of The Fellow on Call: The Heme/Onc Podcast, the group closes out their hemophilia series.
The group delineates the acute management of hemophilia patients, particularly with factor replacement.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.